Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

NASDAQ:CYCC opened at $0.25 on Friday. Cyclacel Pharmaceuticals has a 1-year low of $2.73 and a 1-year high of $49.34. The company has a 50-day moving average of $4.32 and a 200 day moving average of $5.57. The firm has a market cap of $52.68 million, a PE ratio of -0.03 and a beta of 0.52.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) EPS for the quarter, missing the consensus estimate of ($4.64) by ($0.64). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 12,164,301 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $0.48, for a total transaction of $5,838,864.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 68.00% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.